Verona Pharma Stock Discussion

$Verona Pharma (VRNA.US)$
Given the current performance and sector conditions, Verona Pharma poses a moderately high risk 7.5/10, for a trader's portfolio. The company is not profitable, which elevates its risk profile despite the ample cash reserves that provide a financial cushion. The significant positive news may drive short-term gains, but reliance on future drug approvals carries inherent speculative risk. The biotech sector's low interest may dampen broader market enthusiasm, although stoc...

$Verona Pharma (VRNA.US)$ $Safe & Green Development (SGD.US)$ $Globalstar (GSAT.US)$ $SRM Entertainment (SRM.US)$ $Silo Pharma (SILO.US)$ $ESSA Pharma (EPIX.US)$ $SAG Holdings (SAG.US)$ $Tenaya Therapeutics (TNYA.US)$ $Air Transport Services (ATSG.US)$ $Hanryu Holdings (HRYU.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $Singular Genomics (OMIC.US)$ $Nuwellis (NUWE.US)$ $Vast Renewables (VSTE.US)$
📊⚡️📊

$Verona Pharma (VRNA.US)$ monday 4/11 earnings, another shot in the arm towards 40

$Verona Pharma (VRNA.US)$ P/L= -6.44% in 10 days

$Verona Pharma (VRNA.US)$ Wow, the recent earnings - which was not really earnings yet - gave this a greay boost. pre-market i am officially 100% up !

$Verona Pharma (VRNA.US)$ earnings on 8/8 and hopefully new announcements!

$Verona Pharma (VRNA.US)$ and finally it seems all brakes are loose and it is going to the top!

$Verona Pharma (VRNA.US)$ Price pressure has begun in pre-market, which looks unreal for a company receicing approval for a novel - and potentially groundbreaking - drug.
Stay calm, dont play in the hands of the shorts. Make sure your stock cannot be borrowed for shorts as well.

$Verona Pharma (VRNA.US)$ shorters will try to push it down. this is a long term hold being a blockbuster drug, with a 2 billion potential further down the road. revenue forecast for this year 40 million. hopefully conference call is giving the price a boost. if a big pharma might do a take over, it goes sky rocketing. whatever it is, don’t sell cheap. Disclaimer: not financial advice.